8.80Open8.80Pre Close0 Volume437 Open Interest31.00Strike Price0.00Turnover0.00%IV10.04%PremiumMay 16, 2025Expiry Date5.17Intrinsic Value100Multiplier7DDays to Expiry3.63Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma7.16Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Exelixis Stock Discussion
Breakthrough: CABOMETYX Becomes First FDA-Approved Treatment for All Advanced NET Cancers
Exelixis Reveals Breakthrough Cancer Pipeline: 4 Novel Drugs Show Promise in Early Data
2.Based on the fourth-quarter and fiscal year 2024 financial report, Exelixis, Inc. demonstrated excellent performance. For the fourth quarter, the company reported net income of $139.9 millio...
Revolutionary Kidney Cancer Treatment Doubles Patient Survival: Final 5-Year Trial Results Revealed
No comment yet